A patent foramen ovale is a common intracardiac finding that is located between the left and right atrium. It can cause right-to-left shunting and has a high prevalence in patients who suffer a cryptogenic stroke. Earlier trials did not show superiority of percutaneous patent foramen ovale closure with standard medical therapy over standard medical therapy alone in the treatment of cryptogenic stroke. Interestingly, several meta-analyses show positive results regarding closure, suggesting underpowering of the individual trials. Recently, two large prospective trials and one long-term follow-up study showed benefit of percutaneous closure over standard medical therapy in treatment of cryptogenic stroke. A larger right-to-left shunt or the presence of an atrial septal aneurysm were predictors for a recurrent event. Therefore, percutaneous patent foramen ovale closure after cryptogenic stroke should be recommended over antiplatelet therapy alone in patients younger than 55 years of age with a high-risk patent foramen ovale.
CITATION STYLE
Snijder, R. J. R., Suttorp, M. J., Ten Berg, J. M., & Post, M. C. (2018). Percutaneous closure of a patent foramen ovale after cryptogenic stroke. Netherlands Heart Journal, 26(1), 5–12. https://doi.org/10.1007/s12471-017-1063-3
Mendeley helps you to discover research relevant for your work.